These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 29542352)

  • 1. Advances in immunotherapy for acute myeloid leukemia.
    Przespolewski A; Szeles A; Wang ES
    Future Oncol; 2018 Apr; 14(10):963-978. PubMed ID: 29542352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
    Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
    Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in immunotherapy for pediatric acute myeloid leukemia.
    Bonifant CL; Velasquez MP; Gottschalk S
    Expert Opin Biol Ther; 2018 Jan; 18(1):51-63. PubMed ID: 28945115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
    Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
    Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The progress and current status of immunotherapy in acute myeloid leukemia.
    Yang D; Zhang X; Zhang X; Xu Y
    Ann Hematol; 2017 Dec; 96(12):1965-1982. PubMed ID: 29080982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approaches for the immunotherapy of acute myeloid leukemia.
    Geiger TL; Rubnitz JE
    Discov Med; 2015 Apr; 19(105):275-84. PubMed ID: 25977190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
    Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F
    Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current strategies in immunotherapy for acute myeloid leukemia.
    Lichtenegger FS; Schnorfeil FM; Hiddemann W; Subklewe M
    Immunotherapy; 2013 Jan; 5(1):63-78. PubMed ID: 23256799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in acute myeloid leukemia.
    Arpinati M; Curti A
    Immunotherapy; 2014; 6(1):95-106. PubMed ID: 24341888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
    Tettamanti S; Magnani CF; Biondi A; Biagi E
    Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of natural killer cell-targeted therapy for acute myeloid leukemia.
    Kaito Y; Imai Y
    Int J Hematol; 2024 Jul; 120(1):34-43. PubMed ID: 38693419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer cell-based immunotherapy for acute myeloid leukemia.
    Xu J; Niu T
    J Hematol Oncol; 2020 Dec; 13(1):167. PubMed ID: 33287858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in acute myeloid leukemia.
    Grosso DA; Hess RC; Weiss MA
    Cancer; 2015 Aug; 121(16):2689-704. PubMed ID: 26095886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.
    Masarova L; Kantarjian H; Ravandi F; Sharma P; Garcia-Manero G; Daver N
    Adv Exp Med Biol; 2018; 995():97-116. PubMed ID: 30539507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia.
    Restelli C; Ruella M; Paruzzo L; Tarella C; Pelicci PG; Colombo E
    Blood Cancer Discov; 2024 Jul; 5(4):234-248. PubMed ID: 38904305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.
    Daver N; Alotaibi AS; Bücklein V; Subklewe M
    Leukemia; 2021 Jul; 35(7):1843-1863. PubMed ID: 33953290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting.
    Przespolewski AC; Griffiths EA
    Blood Rev; 2020 Sep; 43():100654. PubMed ID: 32029263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia.
    Khoury HJ; Collins RH; Blum W; Stiff PS; Elias L; Lebkowski JS; Reddy A; Nishimoto KP; Sen D; Wirth ED; Case CC; DiPersio JF
    Cancer; 2017 Aug; 123(16):3061-3072. PubMed ID: 28411378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.